Assignee
SERMONIX PHARMACEUTICALS INC
US·2 granted patents·4 pending applications·2 citations·filing 2021–2024
Top patents by PatentIndex Score
6 records- 0190US12023321B2Lasofoxifene treatment of aromatase-resistant ER+cancerSERMONIX PHARMACEUTICALS INC·Filed 2023·Granted Jul 2, 2024·2 cites·30 claims
- 0282US12433866B2Lasofoxifene treatment of aromatase-resistant ER+ cancerSERMONIX PHARMACEUTICALS INC·Filed 2024·Granted Oct 7, 2025·0 cites·30 claims
- 0370US2023149350A1Lasofoxifene treatment of aromatase-resistant er+ cancerSERMONIX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0466US2024122896A1Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitorSERMONIX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0564US2023381138A1Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitorSERMONIX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0653US2022133691A1Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignanciesSERMONIX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SERMONIX PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →